Abstract
Introduction: Lupus erythematosus has been a chronic inflammatory illness where chemokines play a great role in its pathogenesis. CXCL9 and CXCL10 are chemokines that were researched in a variety of inflammatory skin disorders for their crucial role in immune responses.
Aim of the Work: To compare CXCL9 and CXCL10 serum levels in patients suffering from cutaneous versus systemic lupus erythematosus.
Patients and Methods: The forty-five Egyptian patients in this case-control research were collected from the University Hospital's outpatient clinic between October 2018 and June 2019. Two groups of patients were established: DLE Group (Fifteen patients), and SLE group (Thirty patients) and forty control persons. Five ml of blood were obtained from all patients for assessment of serum CXCL9 and CXCL10 by enzme-linked immunosorbemt assay (ELISA) method.
Results: When comparing patients with DLE and SLE to controls, our findings demonstrated highly statistically considerable increases in CXCL9 and CXCLl0 serum levels. Moreover, patients having SLE had a highly statistically considerable rise in both CXCL9 and CXCLl0 serum levels when compared to DLE patients. Meanwhile, when comparing SLE patients having active disease to those having inactive disease, there was a statistically significant rise in CXCL9 and CXCLl0 serum levels.
Conclusion: The chemokines CXCL9 and CXCL10 may have had an etiopathogenesis role in SLE and DLE as they are increased in both DLE and SLE patients. In addition, CXCL10 levels in the serum could be used as a stand-alone biomarker for SLE activity.
Keywords: Systemic lupus erythematosus, discoid lupus erythematosus, CXCL9, CXCL10.